# Amgen Inc. (AMGN) FY2025 YTD Q3 P&L / Income Statement

- Company: Amgen Inc. (AMGN)
- Period: 2025-01-01 to 2025-09-30
- Filing: Q3 FY2025 10-Q, filed 2025-11-05, accession number 0000318154-25-000072
- Page: https://plicit.ai/financials/amgn/fy2025-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/amgn-fy2025-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2025-01-01 through 2025-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 26,885,000,000 US dollars
- **Cost of sales**: 9,061,000,000 US dollars
- **Gross profit (calculated)**: 17,824,000,000 US dollars
- **Operating expenses (calculated)**: 11,464,000,000 US dollars
- **Operating income**: 6,360,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,102,000,000 US dollars
- **Income before income taxes**: 7,462,000,000 US dollars
- **Provision for income taxes**: 1,084,000,000 US dollars
- **Net income**: 6,378,000,000 US dollars
- **Aranesp - UNITED STATES**: 301,000,000 US dollars
- **Aranesp - Non-US**: 755,000,000 US dollars
- **BLINCYTO - UNITED STATES**: 779,000,000 US dollars
- **BLINCYTO - Non-US**: 367,000,000 US dollars
- **EVENITY - UNITED STATES**: 1,132,000,000 US dollars
- **EVENITY - Non-US**: 369,000,000 US dollars
- **ENBREL - UNITED STATES**: 1,675,000,000 US dollars
- **ENBREL - Non-US**: 19,000,000 US dollars
- **KRYSTEXXA - UNITED STATES**: 905,000,000 US dollars
- **KRYSTEXXA - Non-US**: 0 US dollars
- **Kyprolis - UNITED STATES**: 673,000,000 US dollars
- **Kyprolis - Non-US**: 388,000,000 US dollars
- **Nplate - UNITED STATES**: 762,000,000 US dollars
- **Nplate - Non-US**: 377,000,000 US dollars
- **Otezla - UNITED STATES**: 1,328,000,000 US dollars
- **Otezla - Non-US**: 312,000,000 US dollars
- **Other products - UNITED STATES**: 3,907,000,000 US dollars
- **Other products - Non-US**: 1,283,000,000 US dollars
- **Prolia - UNITED STATES**: 2,271,000,000 US dollars
- **Prolia - Non-US**: 1,089,000,000 US dollars
- **Repatha - UNITED STATES**: 1,146,000,000 US dollars
- **Repatha - Non-US**: 1,000,000,000 US dollars
- **TEPEZZA - UNITED STATES**: 1,349,000,000 US dollars
- **TEPEZZA - Non-US**: 97,000,000 US dollars
- **TEZSPIRE - UNITED STATES**: 1,004,000,000 US dollars
- **TEZSPIRE - Non-US**: 0 US dollars
- **Vectibix - UNITED STATES**: 441,000,000 US dollars
- **Vectibix - Non-US**: 415,000,000 US dollars
- **XGEVA - UNITED STATES**: 1,064,000,000 US dollars
- **XGEVA - Non-US**: 573,000,000 US dollars
- **Product sales - UNITED STATES**: 18,737,000,000 US dollars
- **Product sales - Non-US**: 7,044,000,000 US dollars
- **Selling, general and administrative**: 5,098,000,000 US dollars
- **Research and development**: 5,130,000,000 US dollars
- **Other**: 1,236,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 51,562,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 24,677,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

## Chart details: Revenue by Product and Service (16 categories)

- Page: https://plicit.ai/financials/amgn/fy2025-ytd-q3-income-statement/revenue-by-product-and-service-16-categories
- Chart image: https://plicit.ai/charts/amgn-fy2025-ytd-q3-revenue-by-product-and-service-16-categories-sankey.png

Income statement for 2025-01-01 through 2025-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 26,885,000,000 US dollars
- **Cost of sales**: 9,061,000,000 US dollars
- **Gross profit (calculated)**: 17,824,000,000 US dollars
- **Operating expenses (calculated)**: 11,464,000,000 US dollars
- **Operating income**: 6,360,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,102,000,000 US dollars
- **Income before income taxes**: 7,462,000,000 US dollars
- **Provision for income taxes**: 1,084,000,000 US dollars
- **Net income**: 6,378,000,000 US dollars
- **Prolia**: 3,360,000,000 US dollars
- **Repatha**: 2,146,000,000 US dollars
- **ENBREL**: 1,694,000,000 US dollars
- **Otezla**: 1,640,000,000 US dollars
- **XGEVA**: 1,637,000,000 US dollars
- **EVENITY**: 1,501,000,000 US dollars
- **TEPEZZA**: 1,446,000,000 US dollars
- **BLINCYTO**: 1,146,000,000 US dollars
- **Nplate**: 1,139,000,000 US dollars
- **Kyprolis**: 1,061,000,000 US dollars
- **Aranesp**: 1,056,000,000 US dollars
- **TEZSPIRE**: 1,004,000,000 US dollars
- **KRYSTEXXA**: 905,000,000 US dollars
- **Vectibix**: 856,000,000 US dollars
- **Other products**: 5,190,000,000 US dollars
- **Other revenues**: 1,104,000,000 US dollars
- **Selling, general and administrative**: 5,098,000,000 US dollars
- **Research and development**: 5,130,000,000 US dollars
- **Other**: 1,236,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/amgn/fy2025-ytd-q3-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/amgn-fy2025-ytd-q3-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2025-01-01 through 2025-09-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 26,885,000,000 US dollars
- **Cost of sales**: 9,061,000,000 US dollars
- **Gross profit (calculated)**: 17,824,000,000 US dollars
- **Operating expenses (calculated)**: 11,464,000,000 US dollars
- **Operating income**: 6,360,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,102,000,000 US dollars
- **Income before income taxes**: 7,462,000,000 US dollars
- **Provision for income taxes**: 1,084,000,000 US dollars
- **Net income**: 6,378,000,000 US dollars
- **Product sales**: 25,781,000,000 US dollars
- **Other revenues**: 1,104,000,000 US dollars
- **Selling, general and administrative**: 5,098,000,000 US dollars
- **Research and development**: 5,130,000,000 US dollars
- **Other**: 1,236,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.